232 related articles for article (PubMed ID: 11830325)
1. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.
Stiehl A; Rudolph G; Klöters-Plachky P; Sauer P; Walker S
J Hepatol; 2002 Feb; 36(2):151-6. PubMed ID: 11830325
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
Stiehl A; Rudolph G; Sauer P; Benz C; Stremmel W; Walker S; Theilmann L
J Hepatol; 1997 Mar; 26(3):560-6. PubMed ID: 9075663
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.
Gotthardt DN; Rudolph G; Klöters-Plachky P; Kulaksiz H; Stiehl A
Gastrointest Endosc; 2010 Mar; 71(3):527-34. PubMed ID: 20189511
[TBL] [Abstract][Full Text] [Related]
4. Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis.
Stiehl A; Rost D
Clin Rev Allergy Immunol; 2005 Apr; 28(2):159-65. PubMed ID: 15879621
[TBL] [Abstract][Full Text] [Related]
5. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.
Rudolph G; Gotthardt D; Klöters-Plachky P; Kulaksiz H; Rost D; Stiehl A
J Hepatol; 2009 Jul; 51(1):149-55. PubMed ID: 19410324
[TBL] [Abstract][Full Text] [Related]
6. Primary sclerosing cholangitis: the role of endoscopic therapy.
Stiehl A
Semin Liver Dis; 2006 Feb; 26(1):62-8. PubMed ID: 16496234
[TBL] [Abstract][Full Text] [Related]
7. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.
Rudolph G; Gotthardt D; Kloeters-Plachky P; Rost D; Kulaksiz H; Stiehl A
J Hepatol; 2010 Aug; 53(2):313-7. PubMed ID: 20472317
[TBL] [Abstract][Full Text] [Related]
8. Impact of dominant stenoses on the serum level of the tumor marker CA19-9 in patients with primary sclerosing cholangitis.
Petersen-Benz C; Stiehl A
Z Gastroenterol; 2005 Jun; 43(6):587-90. PubMed ID: 15986288
[TBL] [Abstract][Full Text] [Related]
9. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
10. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
Rudolph G; Kloeters-Plachky P; Rost D; Stiehl A
Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):487-91. PubMed ID: 17489059
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
12. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
[TBL] [Abstract][Full Text] [Related]
14. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis.
Tischendorf JJ; Krüger M; Trautwein C; Duckstein N; Schneider A; Manns MP; Meier PN
Endoscopy; 2006 Jul; 38(7):665-9. PubMed ID: 16673310
[TBL] [Abstract][Full Text] [Related]
15. Poor outcome in progressive sclerosing cholangitis after septic shock.
Kulaksiz H; Heuberger D; Engler S; Stiehl A
Endoscopy; 2008 Mar; 40(3):214-8. PubMed ID: 18264887
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
Hay JE
Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for primary sclerosing cholangitis.
Sinakos E; Lindor K
Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):473-88. PubMed ID: 20678020
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic treatment of primary sclerosing cholangitis.
Parlak E; Kuran SO; Dişibeyaz S; Ciçek B; Oğuz D; Sahin B
Turk J Gastroenterol; 2004 Sep; 15(3):144-8. PubMed ID: 15492911
[TBL] [Abstract][Full Text] [Related]
20. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
